Lazard Asset Management
IMCR icon

Lazard Asset Management’s Immunocore IMCR Stock Holding History

Lazard Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,839
Closed -$237K – 1971
2025
Q4 		$237K Hold
6,839
– – ﹤0.01% 1603
2025
Q3 		$248K Sell
6,839
-82,048
-92% -$2.79M ﹤0.01% 1540
2025
Q2 		$2.79M Buy
+88,887
New +$2.76M ﹤0.01% 900
2024
Q1 		– Sell
-16,837
Closed -$1.15M – 2201
2023
Q4 		$1.15M Buy
+16,837
New +$875K ﹤0.01% 925

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Lazard Asset Management's IMCR Position: Q1 2026 in Review

Lazard Asset Management sold out of Immunocore (IMCR) in Q1 2026, closing a stake of 6,839 shares — an estimated $237K sold.

Lazard Asset Management first reported a position in IMCR in Q4 2023 and held it in 4 quarters. The position peaked at $2.79M in Q2 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Lazard Asset Management reported no remaining Immunocore position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 6,839 Immunocore shares in Q1 2026, an estimated $237K.
  • Lazard Asset Management first reported a position in Immunocore in Q4 2023 and held it in 4 quarters.
  • Lazard Asset Management's Immunocore position peaked at $2.79M in Q2 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.